Our Products & Services

Invivoscribe and its subsidiaries provide one stop access to clinically-validated personalized molecular diagnostics and cutting edge testing for physicians and cancer centers in over 50 countries world wide, enabling doctors to determine the most successful method of treatment for each individual patient. Currently we provide the majority of all molecular reagents and products for leukemia and lymphoma testing. Invivoscribe's products are used to identify, classify and monitor leukemias, lymphomas and other lymphoproliferative diseases. The company's CLIA- and CAP- accredited clinical reference laboratory, LabPMM, is the only laboratory outside Japan licensed to perform FLT3 biomarker testing.

Invivoscribe provides a comprehensive selection of PCR-based gene rearrangement, chromosome translocation, and gene mutation testing reagents and controls. Customers include many of the world’s leading pharmaceutical and biotechnology companies, medical centers, cancer research centers, reference laboratories and molecular testing centers. As a contract research organization, Invivoscribe provides tests and services to assist in the development of pharmaceutical agents and devices.

Our CE-marked in vitro diagnostic (IVD) products, which are available for sale and use only outside of North America, target biomarkers that have demonstrated clinical utility. These tests are used to identify, stratify and monitor hematologic cancers.

Our companion diagnostic products assist in the development of pharmaceutical agents and devices. All of our gene rearrangement products and the majority of our gene mutation testing products are covered by exclusive-licensed patents.